1 – 10 of 18
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
End-stage renal disease associated with prophylactic lithium treatment.
(
- Contribution to journal › Article
-
Mark
Twelve months of electronic monitoring (MEMS®) in the Swedish COAST-study : a comparison of methods for the measurement of adherence in schizophrenia
(
- Contribution to journal › Article
- 2013
-
Mark
Vulnerability versus resilience to prenatal stress in male and female rats; Implications from gene expression profiles in the hippocampus and frontal cortex
(
- Contribution to journal › Article
-
Mark
A modified Drug Attitude Inventory used in long-term patients in sheltered housing.
(
- Contribution to journal › Article
-
Mark
Drug attitude and other predictors of medication adherence in schizophrenia : 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study
(
- Contribution to journal › Article
- 2012
-
Mark
DAI-10 is as good as DAI-30 in schizophrenia
(
- Contribution to journal › Article
- 2011
-
Mark
Cost of disorders of the brain in Europe 2010
(
- Contribution to journal › Article
- 2010
-
Mark
Changes in cerebrospinal fluid insulin during non-neurological surgery
2010) 23rd Congress Meeting of European-College-of-Neuropsychopharmacology In European Neuropsychopharmacology 20. p.328-329(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Interventions in antipsychotics-treated patients with cardiometabolic risk factors or metabolic syndrome
2008) 21st Congress of the European-College-of-Neuropsychopharmacology In European Neuropsychopharmacology 18(S4). p.440-441(
- Contribution to journal › Published meeting abstract
-
Mark
Content versus delivery: Challenges and options in the treatment of schizophrenia
(
- Contribution to journal › Debate/Note/Editorial